Melanoma: Molecular Mechanism and New Agents for Prevention and Therapy
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".
Deadline for manuscript submissions: 30 August 2025 | Viewed by 76
Special Issue Editor
Interests: melanoma; drug resistance melanoma; melanoma cells migration; melanoma cells invasion, apoptosis; melanoma epigenetics; cell cycle; signal transduction
Special Issue Information
Dear Colleagues,
Malignant melanoma is the most aggressive epithelial tumor with a high capacity to metastasize to various organs. Although available treatments for metastatic melanoma have significantly improved the clinical outcome of patients, there is still too large a portion of patients whose tumor progresses. This is due to the high plasticity of melanoma cells and their complex interaction with the tumor microenvironment, which can strongly influence their behavior, regulating tumor progression, and their response to therapies, leading to the development of resistance mechanisms. Therefore, new therapeutic approaches for melanoma are needed. This Special Issue aims to collect studies on the molecular mechanisms underlying melanomagenesis and tumor progression, on the identification of new targets and/or potential predictive or prognostic markers, as well as on the use of new molecules, including natural substances, for therapy. Original experimental research, review articles, and commentaries are considered.
Dr. M. Letizia Motti
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- melanoma
- therapy resistance
- melanoma microenvironment (MME)
- melanoma plasticity
- epigenetic mechanism
- predictive markers
- prognostic markers
- extracellular vesicles
- molecular therapy
- natural molecules
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
